Drugs / NCP112
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06263998 | Jul 2024 → Nov 2025 overdue | xerophthalmia | Huons Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT05638165 | Oct → Nov 2021 | atopic eczema | NovaCell Technology Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2021-01-28 | NovaCell Technology Inc. | Regulatory 노바셀테크놀로지, 아토피 치료제 국내 임상 1상 승인 novacelltech.com ↗
동구바이오제약은 계열사 노바셀테크놀로지가 면역치료제 후보물질 "NCP112"를 이용한 아토피 피부염 치료제의 임상 1상을 식품의약품안전처로부터 승인받았다고 28일 밝혔다. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2021-01-28 | NovaCell Technology Inc. | 노바셀테크놀로지, 아토피 치료제 국내 임상 1상 승인 novacelltech.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NCP112 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05638165 ↗ |
| Route | Topical | “topical application of NCP112 or placebo (vehicle)” NCT05638165 ↗ |